Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: Interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA

Antiviral Research

Volumn 59, Issue 2, 2003, Pages 111-119

  Dix, Richard D ^a   Podack, Eckhard R ^b   Cousins, Scott W ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cytokine immunotherapy; Cytomegalovirus retinitis; Interleukin 2; MAIDS; Perforin cytotoxicity

Indexed keywords

INTERLEUKIN 2; MESSENGER RNA; PERFORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINITIS; RETROVIRUS; TISSUE LEVEL; TREATMENT OUTCOME;

CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0038560449     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00066-4     Document Type: Article

References (52)

1. Atherton S.S., Newell C.K., Kanter M.Y., Cousins S.W. Retinitis in euthymic mice following inoculation of murine cytomegalovirus (MCMV) via the supraciliary route. Curr. Eye Res. 10:1991;667-677.
2. Bloom J.N., Palenstine A.G. The diagnosis of cytomegalovirus retinitis. Ann. Intern. Med. 15:1988;963-969.
3. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey R.T. Jr., Dybul M., Kovacs J.A., Metcalf J.A., Mican J.M., Berrey M.M., Corey L., Lane H.C., Fauci A.S. Effect of interleukin-2 on the pool of latently-infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nature Med. 5:1999;651-655.
4. Clark W.R., Walsh C.M., Glass A.A., Huang M.T.F., Ahmed R., Matloubian M. Cell-mediated cytotoxicity in perforin-less mice. Intern. Rev. Immunol. 13:1995;1-14.
5. Clerici M., Shearer G.M. A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today. 14:1993;107-111.
6. Connors M., Kovacs J.A., Drevat S., Gea-Banacloche J.C., Sneller M.C., Flanigan M., Metcalf J.A., Walker R.E., Falloon J., Baseler M., Feuerstein I., Masur H., Lane H.C. HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med. 3:1997;533-540.
7. Cunningham E.T., Margolis T.P. Ocular manifestations of HIV infection. N. Engl. J. Med. 339:1998;236-244.
8. Davey R.T. Jr., Chaitt D.G., Piscitelli S.C., Wells M., Kovacs J.A., Walker R.E., Falloon J., Polis M.A., Metcalf J.A., Masur H., Fyfe G., Lane H.C. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175:1997;781-789.
9. Davey R.T. Jr., Chaitt D.G., Albert J.M., Piscetelli S.C., Kovacs J.A., Walker R.E., Falloon J., Polis M.A., Metcalf J.A., Masur H., Dewar R., Baseler M., Fyfe G., Giedlin M.A., Lane H.C. A randomized trial of high-dose versus low-dose subcutaneous interleukin-2 outpatient therapy for early immunodeficiency virus type 1 infection. J. Infect. Dis. 179:1999;849-858.
10. Deng G., Podack E.R. Suppression of apoptosis in a cytotoxic T cell line by interleukin-2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2189-2193.
11. Dix R.D. Systemic murine cytomegalovirus infection of mice with retrovirus-induced immunodeficiency results in ocular infection but not retinitis. Ophthalmic Res. 30:1998;295-301.
12. Dix, R.D., Cousins, S.W., 2003. Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased intraocular CD8+ T cell infiltration. Ophthalmic Res., in press.
13. Dix R.D., Cray C.C., Cousins S.W. Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis. Curr. Eye Res. 13:1994;587-595.
14. Dix R.D., Cray C.C., Cousins S.W. Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS). Ophthalmic Res. 29:1997a;381-392.
15. Dix R.D., Giedlin M., Cousins S.W. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. Invest. Ophthalmol. Vis. Sci. 38:1997b;1411-1417.
16. Dix R.D., Podack E.R., Cousins S.W. Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis. J. Virol. 77:2003;3402-3408.
17. Fay M.T., Freeman W.R., Wiley C.A., Hardy D., Bozzette S. Atypical retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 105:1988;483-490.
18. Gao E.-R., Yu X.-H., Lin P.-C., Zhang H., Kaplan H.J. Intraocular viral replication after systemic murine cytomegalovirus infection requires immunosuppression. Invest. Ophthalmol. Vis. Sci. 36:1995;2322-2327.
19. Gazzinelli R.T., Makino M., Chattopadhyay S.K., Snapper C.M., Sher A., Hugin A.W., Morse H.C. III CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J. Immunol. 148:1992;182-188.
20. Goldstein P. Fas-based T cell-mediated cytotoxicity. Curr. Topics Microbiol. Immunol. 198:1995;25-37.
21. Hartley J.W., Frederickson T.N., Yetter R.A., Makino M., Morse H.C. III Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63:1989;1223-1231.
22. Holland, G.N., Tufail, A., Jordan, M.C., 1996. Cytomegalovirus disease. In: Pepose, J.S., Holland, G.N., Wilhelmus, K.R. (Eds.), Ocular Infections and Immunity. Mosby-Year Book, St. Louis, MO, pp. 1088-1130.
23. Jabs D.A., Bartlett J.G. AIDS and ophthalmology: a period of transition. Am. J. Ophthalmol. 124:1997;227-233.
24. Jabs D.A., Enger C., Bartlett J.G. Cytomegalovirus retinitis and acquried immunodeficiency syndrome. Arch. Ophthalmol. 107:1989;75-80.
25. Jacobson M.A., Stanley S., Holtzer C., Margolis T.P., Cunningham E.T. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30:2000;232-233.
26. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study AIDS pathogenesis. FASEB J. 5:1991;2398-2405.
27. Kagi D., Ledermann B., Burki K., Seiler P., Odermatt B., Olsen K.J., Podack E.R., Zindernagel R.M., Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:1994;313-337.
28. Kagi D., Vignaux F., Ledermann B., Burki K., Depraitere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 265:1994;528-530.
29. Kercher L., Mitchell B.M. Immune transfer protects severely immunosuppressed mice from murine cytomegalovirus retinitis and reduces the viral load in ocular tissue. J. Infect. Dis. 182:2000;652-661.
30. Kovacs J.A., Baseler M., Dewar R.J., Vogel S., Davey R.T. Jr., Falloon J., Polis M.A., Walker R.E., Stevens R., Salzman N.P. Increases in CD4+ T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N. Engl. J. Med. 332:1995;567-575.
31. Kovacs J.A., Vogel S., Albert J.M., Falloon J., Davey R.T. Jr., Walker R.E., Polis M.A., Spooner K., Metcalf J.A., Baseler M., Fyfe G., Lane H.C. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N. Engl. J. Med. 335:1996;1350-1356.
32. Kovacs J.A., Imamichi H., Vogel S., Metcalf J.A., Dewar R.L., Baseler M., Stevens R., Adelsberger J., Lambert L., Davey R.T. Jr., Walker R.E., Falloon J., Polis M.A., Masur H., Lane H.C. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J. Infect. Dis. 182:2000;1063-1069.
33. Kovacs J.A., Vogel S., Metcalf J.A., Baseler M., Stevens R., Adelsberger J., Lempicki R., Hengel R.L., Sereti I., Lambert L., Dewar R.L., Davey R.T. Jr., Walker R.E., Falloon J., Polis M.A., Masur H., Lane H.C. Interleukin-2-induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur. J. Immunol. 31:2001;1351-1360.
34. Lowin B., Beermann F., Schmidt A., Tschopp J. A null mutation in the perforin gene impairs cytolytic T-lymphocyte- and natural killer cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11571-11575.
35. Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 370:1994;650-652.
36. Lowin B., Peitsch M.C., Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T-lymphocyte and natural killer cell-mediated cytotoxicity. Curr. Topics Microbiol. Immunol. 198:1995;1-24.
37. Miller K.D., Spooner K., Herpin B.R., Rock-Kress D., Metcalf J.A., Davey R.T. Jr., Falloon J., Kovacs J.A., Polis M.A., Walker R.E., Masur H., Lane H.C. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expression. Clin. Immunol. 99:2001;30-42.
38. Mitsuyasu R.T. The potential role of interleukin-2 in HIV. AIDS. 15(Suppl. 2):2001;S22-S27.
39. Morse H.C. III, Yetter R.A., Via C.S., Hardy R.R., Cerny A., Hayakawa K., Hugin A.W., Miller M.N., Holmes K.L., Shearer G.M. Functional and phenotypic alterations in T cell subsets during the course of MAIDS, a murine retrovirus-induced immunodeficiency syndrome. J. Immunol. 143:1989;844-849.
40. Morse H.C. III, Chattopadhyat S.K., Makino M., Fredrickson T.N., Hugin A.W., Hartley J.W. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model of AIDS. AIDS. 6:1992;607-621.
41. Mosier D.E., Yetter R.A., Morse H.C. III Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 161:1985;766-784.
42. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449-1461.
43. Nagata S., Suda T. Fas and Fas ligand. Lpr and gld mutations. Immunol. Today. 16:1995;39-43.
44. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
45. Palella F.J. Jr., Delaney K.M., Moorman A.C., Loveless J.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:1998;853-860.
46. Podack E.R. Perforin, killer cells and gene transfer immunotherapy for cancer. Curr. Topics Microbiol. Immunol. 198:1995;121-130.
47. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:2002;323-370.
48. Smith K.A. Interleukin-2: inception, impact, and implications. Science. 240:1988;1169-1176.
49. Smith K.A. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T cell immunity without toxicity. AIDS. 15(Suppl. 2):2001;S28-S35.
50. Smyth M.J., Trapani J.A. The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology. J. Virol. 72:1998;1-9.
51. Walsh C.M., Matloubian M., Liu C.-C., Ueda R., Kurahara C.G., Christensen J.L., Huang M.T.F., Young J.D.-E., Ahmed R., Clark W.R. Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10854-10854.
52. Weissman D., Dybul M., Daucher M.B., Davey R.T. Jr., Walker R.E., Kovacs J.A. Interleukin-2 upregulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J. Infect. Dis. 181:2000;933-938.